Latest news with #PharmaceuticalSchedule
Otago Daily Times
4 days ago
- Health
- Otago Daily Times
Private use of publicly-funded cancer drugs will widen inequities, doctors warn
By Ruth Hill of RNZ A move to allow private patients to access publicly-funded cancer drugs threatens to increase wait times for those in the public system, warn senior doctors. Under "transitional access", which comes into effect on July 1, private patients who are already receiving treatment - or about to start treatment - with a newly funded medicine will not have to shift to the public system for 12 months. Associate Health Minister David Seymour, who has championed the rule change, said it would lessen stress on private patients by enabling continuity of care, and pressure on the public system which would no longer have to deal with a sudden influx of patients. However, the move has been criticised by opposition politicians as "a subsidy for private insurers", which already cover the cost of medicines newly funded by Pharmac, and of little benefit to patients. The Association of Salaried Medical Specialists, which represents 6500 senior hospital doctors and dentists, said its members working in oncology and haematology had "significant concerns" the change would widen inequities for patients. Change will create 'two-tier' waiting list In a letter on June 13 to Pharmac's acting chief executive Brendan Boyle, the union's director of policy and research, Harriet Wild, quoted a briefing to the minister saying the policy change "would not increase volumes of cancer medicines provided in New Zealand, as only the location of treatments will change". "It will simply shift some of the existing capacity to the private system, where patients will need to fund infusion costs out-of-pocket," Wild wrote. "There will be pressure on the public system to ensure a smooth transition in treatment regime, which may mean delaying treatment for other people already waiting on the public list and unable to self-fund to start in private. "This potentially creates a two-tier waiting list and a system where those with more financial resources, will be prioritised for treatment." Furthermore, the shift of resources and inevitable increase in demand was likely to speed up the exodus of staff to the private sector, making public waiting lists even longer. Minister signals broadening access further A "back-pocket Q&A" provided to Seymour ahead of a Cabinet meeting on April 7 noted that the current eligibility criteria in the Pharmaceutical Schedule (excluding patients in private settings) was "designed to ensure public funding for medicines was prioritised for those managed in the public health system for cancer treatment, assessed by need, rather than public funding supporting those who chose to access treatment in private facilities. "Often the private treatment is funded from private health insurance that people have paid premiums into." In the same document, the minister said there was no plan to expand the policy to include other types of medicines or treatments "at this stage". "With that said, I've asked the Ministry [of Health] to do further work in this area to explore the possibility of broadening access to all publicly-funded medicines in private facilities - not just newly funded cancer medicines. "I encourage the private health providers and insurance companies to work closely with the ministry to support their understanding of how this might work in practice." Wild said opening access to publicly-funded drugs even wider would pull more staff away from the public system, reducing access for the majority who relied on it. "That would establish a system where a patient's ability to receive timely cancer care would depend on whether they could afford the out-of-pocket infusion costs." Pharmac's Budget boost needs 'back up' The government's 2024 Budget boost to Pharmac to widen access to medicines for patients had not been accompanied by extra resources for Te Whatu Ora to deliver the treatments, when public oncology services were already swamped with demand, Wild said. "Our members are increasingly needing to manage deteriorating patients, who are unable to access chemotherapy infusions in clinically acceptable timeframes. "This is unacceptable and represents a significant failure to invest in a planned and co-ordinated way to enable the public system to meet the needs of cancer patients, including those eligible for newly funded cancer medicines. "Whenever a new cancer drug is funded, it must be accompanied by an increase in the full package of care (staffing, infusion space, pharmacy) so that patients can actually receive the medicines within clinically acceptable timeframes." The Health Minister and David Seymour's office have been approached for comment.
Scoop
26-05-2025
- Health
- Scoop
Schedule Rule Changes Will Improve Continuity Of Cancer Care
Pharmac is proposing a change to the Pharmaceutical Schedule rules, which if agreed, would give New Zealanders with cancer greater continuity of care. Pharmac is consulting on a proposal to amend the rules of the Pharmaceutical Schedule, following the Government's decision to enable access to new publicly funded cancer medicines in private hospitals and clinics from 1 August 2025. 'When Pharmac funds a new cancer medicine, there may be some people who have already started this treatment in a private health care facility. Currently, if this person wants their cancer medicine funded, they need to transition back into the public system during their treatment,' Director Strategy, Policy and Performance Michael Johnson says. Johnson says that the rule change Pharmac is consulting on will enable public hospitals to supply medicines to eligible private facilities and claim a subsidy from Pharmac in the same way as they do for medicines delivered within a public hospital. If approved, from 1 August 2025, public hospitals would be able to supply newly funded cancer medicines (those where funding begins on or after 1 August 2025) to private facilities to administer to their patients, where either: the person is already receiving treatment at the date that their medicine becomes funded by Pharmac, or the person has an approved treatment plan, and is about to start treatment, at the date that the medicine becomes funded by Pharmac. Funded medicine could be supplied to a private facility for the remainder of a person's treatment course, for up to 12 months. 'Your input is valuable and helps us make better decisions. Let us know what you think by 13 June,' Johnson says. Consultation on this proposal opens today and closes on 13 June. All feedback received before the closing date will be considered prior to making a decision on this proposal. Feedback can be emailed to consult@
